Advertisement

Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas

  • Koji MatsuoEmail author
  • Michele L. Eno
  • Dwight D. Im
  • Neil B. Rosenshein
Original Article

Abstract

Objective

To evaluate drug resistance after exposure to neoadjuvant chemotherapy and to postoperative chemotherapy in epithelial ovarian, fallopian, and primary peritoneal carcinomas.

Methods

In vitro drug resistance assay results (EDR Assay, Oncotech, Inc.) for platinum and taxane were evaluated for the following three groups: (1) primary cytoreductive surgery without prior chemotherapy; (2) primary cytoreductive surgery after neoadjuvant chemotherapy with platinum and taxane; and (3) recurrent cases after postoperative chemotherapy with platinum and taxane. Proportions of extreme drug resistance (EDR) were analyzed with Fisher’s exact test.

Results

There were 277 cases that underwent primary cytoreductive surgery without prior chemotherapy: 14 cases of primary cytoreductive surgery after neoadjuvant chemotherapy with platinum and taxane, and 65 recurrent cases. Primary cytoreductive cases following neoadjuvant chemotherapy displayed an increased proportion of EDR to platinum agents compared to primary cytoreductive surgery without prior chemotherapy: neoadjuvant versus non-neoadjuvant, cisplatin 30 versus 7.3%, OR 5.4, 95%CI 1.3–23.2, P = 0.027; carboplatin 33.3 versus 9.2%, OR 4.9, 95%CI 1.4–17.6, P = 0.038. There were no differences in the proportion of EDR to taxanes between the two groups. On the contrary, recurrent cases showed an increased proportion of EDR to paclitaxel compared to primary cytoreductive surgery without prior chemotherapy: recurrent versus primary, paclitaxel 33.3 versus 21.1%, OR 1.9, 95%CI 1.0–3.5, P = 0.031. There were no differences in the proportion of EDR for platinum and docetaxel between the two groups. Among recurrent cases, there was statistical significance between proportion of paclitaxel EDR and time interval of initial and recurrent surgeries (R 2 0.143, P = 0.011). Recurrent surgery after 5 years from initial cytoreduction was significantly associated with increased proportion of EDR to paclitaxel: 61.5 versus 22.6%, OR 5.5, 95%CI 1.35–22.2, P = 0.011.

Conclusions

Platinum resistance was common after neoadjuvant chemotherapy, while paclitaxel resistance was common after postoperative chemotherapy.

Keywords

Platinum resistance Taxane resistance Neoadjuvant chemotherapy Ovarian cancer 

Notes

Conflict of interest statement

None.

References

  1. 1.
    Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96. doi: 10.3322/CA.2007.0010 CrossRefPubMedGoogle Scholar
  2. 2.
    Heintz AP, Odicino F, Maisonneuve P et al (2003) Carcinoma of the ovary. Int J Gynaecol Obstet 83S:135–166. doi: 10.1016/S0020-7292(03)90118-4 CrossRefGoogle Scholar
  3. 3.
    McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6. doi: 10.1056/NEJM199601043340101 CrossRefPubMedGoogle Scholar
  4. 4.
    Modesitt SC, Jazaeri AA (2007) Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Expert Opin Pharmacother 8:2293–2305. doi: 10.1517/14656566.8.14.2293 CrossRefPubMedGoogle Scholar
  5. 5.
    EDR Assay®, http://www.oncotech.com. Cited 1 October 2008
  6. 6.
    Kern DH, Weisenthal LM (1990) Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 82:582–588. doi: 10.1093/jnci/82.7.582 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Koji Matsuo
    • 1
    Email author
  • Michele L. Eno
    • 1
  • Dwight D. Im
    • 1
    • 2
  • Neil B. Rosenshein
    • 1
    • 2
  1. 1.Department of Obstetrics, Gynecology, and Reproductive SciencesUniversity of Maryland School of MedicineBaltimoreUSA
  2. 2.The Gynecologic CenterMercy Medical CenterBaltimoreUSA

Personalised recommendations